Gyros AB

Gyros appoints Dr. Jack Johansen and Mr. Lars Eric Utterman as Non-executives Directors to the Board of Directors

Pressmeddelande   •   Jul 07, 2009 10:54 CEST

Gyros® AB, the leading provider of automated micro-immunoassays for therapeutic protein development, has appointed Dr. Jack Johansen and Mr. Lars Eric Utterman as Non-executive Directors to its Board of Directors. These appointments bring significant executive and board level experience for the development and commercialization of novel technologies used in biopharmaceutical discovery and development. The appointments follow the recent completion of a successful equity fundraising that saw the company raise SEK 80 million (approximately €7.4m) from its existing investors to drive the further commercialization of its Gyrolab® technology.

Jack Johansen is as an executive consultant to various life science/venture capital companies, including Novo A/S. From 1995-2001, he was a founding CEO of two life science diagnostic companies, Boston Biosystems, Inc. and Boston Probes, Inc., both of which were sold. Prior to this, he was Executive Vice President of science and technology at Millipore Corporation and President of Millicorp, which is Millipore's venture fund. Dr. Johansen is Chairman of the Board of Directors of Protein Forest, Inc. and AdvanDx Inc. and serves on the Board of Directors of Symphogen A/S and 7TM A/S.

Lars Eric Utterman is Chairman of the board of Ludesi AB and Cellectricon AB and board member of LIVC Technologies GmbH. As an executive consultant he was engaged by Gyros during 2008 and now serves as interim manager of IonGate Biosciences GmbH. He has held a number of executive positions at international level for more than 30 years with GE Healthcare, Amersham, Pharmacia and Boehringer Mannheim (now Roche Diagnostics).

Per Carendi, Chairman of Gyros and CEO of SLS Invest, its lead investor, said, "I am pleased Jack and Lars are joining the Gyros board and very much look forward to Gyros benefiting from their experience and expertise in developing and commercializing technologies for the life sciences industry. Their contribution will be crucial as we look to drive the further commercialization of our Gyrolab platform for accelerating the development of therapeutic proteins."

For further information, please contact:

Erik Walldén, CEO
Tel: +46 18-56 64 00
erik.wallden@gyros.com

Notes to editors:

About Gyros AB

Gyros® is the world leader in automated micro-immunoassays for therapeutic protein development.

Gyrolab®, the company's automated and open platform, is a versatile analytical tool that dramatically reduces the time required to optimize and execute immunoassays. Time for assay optimization is often cut from weeks, to a matter of days. This results in increased efficiency in process development and in clinical evaluation of therapeutic proteins. The ease of assay transfer is unsurpassed in the industry.

Gyrolab enables assays to be conducted with a significantly reduced background, increased dynamic range and with higher throughput. All this is achieved using only nanoliter volumes of reagents and sample. More data can be generated in less time and with higher precision, consequently improving productivity and effectiveness. Applications span the entire spectrum for immunoassays and Gyrolab is now firmly established as the preferred solution for pharmacokinetic (PK) assays in the development of therapeutic proteins.

Many major pharmaceutical companies and service providers - CMOs/CROs - have already implemented multiple Gyrolab platforms to boost their drug development process and to meet increasing regulatory demands on testing. Several validated assays are already in some phase of clinical sample analysis. Gyrolab xP complies with the requirements of 21 CFR part 11 and comprehensive validation support is provided.

The company has over 50 employees based at its headquarters in Uppsala, Sweden and at regional sales and support offices in the USA and Europe.

www.gyros.com